Aptus Pharma Ltd () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

4.0 k (-54.55%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

72.89%

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 183 Cr ()

P/E

62.00

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.00

Return on Equity

0.00%

Price to Book

8.45

Revenue and Profits:

Net Sales:

(Quarterly Results - )

Net Profit:

Total Returns

Total Returns (Price + Dividend)

Dividend Yield (0%)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

95.67%

6 Months

0.0%

1 Year

0.0%

2 Years

0.0%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Aptus Pharma for the last several years.

Risk Adjusted Returns v/s

Returns Beta

Beta has not been calculated since enough price history is not available

News & Corporate Actions

News

No Recent News for the Company

Announcements

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

10-Jan-2026 | Source : BSE

Compliance Certificate under Regulation 74 (5) of SEBI (DP) Regulations 2018

Regulation 30 Disclosure - Entry Into The Urology Therapy Segment

21-Nov-2025 | Source : BSE

Regulation 30 Disclosure - Entry into the Urology Therapy Segment

Intimation Of New Product- ENZYKING SYRUP

12-Nov-2025 | Source : BSE

Intimation of new product- ENZYKING SYRUP

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

EBIT to Interest (avg)

2.91

Debt to EBITDA (avg)

1.71

Net Debt to Equity (avg)

Sales to Capital Employed (avg)

0.82

Tax Ratio

27.80%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

28.87%

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

8.45

EV to EBIT

39.47

EV to EBITDA

37.31

EV to Capital Employed

11.40

EV to Sales

7.22

PEG Ratio

Dividend Yield

ROCE (Latest)

28.87%

ROE (Latest)

13.64%

Technicals key factors

Indicator

Weekly

Monthly

No records

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Kapilbhai Hasmukhbhai Chandarana (11.3%)

Highest Public shareholder

Saint Capital Fund (4.29%)

Individual Investors Holdings

22.97%

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Aptus Pharma"
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Aptus Pharma"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Aptus Pharma"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "alert": "No Annual Results declared by Aptus Pharma"
  }
]

Company CV

About

Company Coordinates

Company Details

Tel:

Registrar Details

Name: MOJO Markets Private Limited (Research Entity) (SEBI Registration No. INH000021942) (CIN:U74900MH2015PTC264951)

Registered & Correspondence Address: Benefice Business House, Office No. 3B, 3rd Floor, C.S. 242, Mathuradas Mills Estate, N.M. Joshi Marg, Tulsi Pipe Road, Lower Parel West, Mumbai- 400013

For queries or grievances, please contact us on support@mojoinfinity.com, Phone : 022-35121239

"Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors."